301 related articles for article (PubMed ID: 35800180)
1. Updates in therapeutic drug monitoring in inflammatory bowel disease.
Lodhia N; Rao S
World J Gastroenterol; 2022 Jun; 28(21):2282-2290. PubMed ID: 35800180
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place.
Truta B
World J Gastroenterol; 2022 Apr; 28(13):1380-1383. PubMed ID: 35645545
[TBL] [Abstract][Full Text] [Related]
4. Medical Management of Inflammatory Bowel Disease.
Rahman S; Patel RK; Boden E; Tsikitis VL
Surg Clin North Am; 2024 Jun; 104(3):657-671. PubMed ID: 38677828
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
6. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring of Biologics in Crohn's Disease.
Grossberg LB; Cheifetz AS; Papamichael K
Gastroenterol Clin North Am; 2022 Jun; 51(2):299-317. PubMed ID: 35595416
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F; Argüelles-Arias F; Hinojosa Del Val J; Iborra Colomino M; Martín-Arranz MD; Menchén Viso L; Muñoz Núñez F; Ricart Gómez E; Sánchez-Hernández JG; Valdés-Delgado T; Guardiola Capón J; Barreiro-de Acosta M; Mañosa Ciria M; Zabana Abdo Y; Gutiérrez Casbas A
Gastroenterol Hepatol; 2024 May; 47(5):522-552. PubMed ID: 38311005
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
10. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RWL;
J Gastroenterol Hepatol; 2019 Aug; 34(8):1296-1315. PubMed ID: 30848854
[TBL] [Abstract][Full Text] [Related]
11. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.
Irving PM; Gecse KB
Gastroenterology; 2022 Apr; 162(5):1512-1524. PubMed ID: 35167865
[TBL] [Abstract][Full Text] [Related]
13. Biologics in Pediatric Inflammatory Bowel Disease.
Kleinhenz J; Wagner E
Pediatr Ann; 2022 Feb; 51(2):e77-e81. PubMed ID: 35156888
[TBL] [Abstract][Full Text] [Related]
14. Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review.
Ballesta-López O; Centelles-Oria M; Marqués-Miñana MR; Megías-Vericat JE; Poveda-Andrés JL
Farm Hosp; 2021 Dec; 45(7):56-63. PubMed ID: 35379111
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
16. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
Bousvaros A
Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
[TBL] [Abstract][Full Text] [Related]
17. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
18. Surgery for Inflammatory Bowel Disease in the Era of Biologics.
Lightner AL
J Gastrointest Surg; 2020 Jun; 24(6):1430-1435. PubMed ID: 32253646
[TBL] [Abstract][Full Text] [Related]
19. Phytochemicals and their potential usefulness in inflammatory bowel disease.
Somani SJ; Modi KP; Majumdar AS; Sadarani BN
Phytother Res; 2015 Mar; 29(3):339-50. PubMed ID: 25572840
[TBL] [Abstract][Full Text] [Related]
20. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ferrante M; D'Haens G; Rutgeerts P; Vermeire S; Van Assche G
Curr Gastroenterol Rep; 2009 Dec; 11(6):504-8. PubMed ID: 19903427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
